1
|
Herrmann K, Erkan M, Dobritz M, Schuster
T, Siveke JT, Beer AJ, Wester HJ, Schmid RM, Friess H, Schwaiger M,
et al: Comparison of 3′-deoxy-3′-[18F]fluorothymidine positron
emission tomography (FLT PET) and FDG PET/CT for the detection and
characterization of pancreatic tumours. Eur J Nucl Med Mol Imaging.
39:846–851. 2012. View Article : Google Scholar : PubMed/NCBI
|
2
|
Nakajo M, Nakajo M, Kajiya Y, Jinguji M,
Mori S, Aridome K, Suenaga T and Tanaka S: High FDG and low FLT
Uptake in a thyroid papillary carcinoma incidentally discovered by
FDG PET/CT. Clin Nucl Med. 37:607–608. 2012. View Article : Google Scholar : PubMed/NCBI
|
3
|
Zander T, Scheffler M, Nogova L, Kobe C,
Engel-Riedel W, Hellmich M, Papachristou I, Toepelt K, Draube A,
Heukamp L, et al: Early prediction of nonprogression in advanced
non-small-cell lung cancer treated with erlotinib by using
[(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron
emission tomography. J Clin Oncol. 29:1701–1708. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Frings V, de Langen AJ, Smit EF, van
Velden FH, Hoekstra OS, van Tinteren H and Boellaard R:
Repeatability of metabolically active volume measurements with
18F-FDG and 18F-FLT PET in non-small cell lung cancer. J Nucl Med.
51:1870–1877. 2010. View Article : Google Scholar : PubMed/NCBI
|
5
|
Yang W, Zhang Y, Fu Z, Yu J, Sun X, Mu D
and Han A: Imaging of proliferation with 18F-FLT PET/CT versus
18F-FDG PET/CT in non-small-cell lung cancer. Eur J Nucl Med Mol
Imaging. 37:1291–1299. 2010. View Article : Google Scholar : PubMed/NCBI
|
6
|
Yamamoto Y, Nishiyama Y, Ishikawa S,
Nakano J, Chang SS, Bandoh S, Kanaji N, Haba R, Kushida Y and
Ohkawa M: Correlation of 18F-FLT and 18F-FDG uptake on PET with
Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J
Nucl Med Mol Imaging. 34:1610–1616. 2007. View Article : Google Scholar : PubMed/NCBI
|
7
|
Buck AK, Halter G, Schirrmeister H,
Kotzerke J, Wurziger I, Glatting G, Mattfeldt T, Neumaier B, Reske
SN and Hetzel M: Imaging proliferation in lung tumors with PET:
18F-FLT versus 18F-FDG. J Nucl Med. 44:1426–1431. 2003.PubMed/NCBI
|
8
|
Burgman P, O'Donoghue JA, Humm JL and Ling
CC: Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl
Med. 42:170–175. 2001.PubMed/NCBI
|
9
|
Pugachev A, Ruan S, Carlin S, Larson SM,
Campa J, Ling CC and Humm JL: Dependence of FDG uptake on tumor
microenvironment. Int J Radiat Oncol Biol Phys. 62:545–553. 2005.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Li XF, Ma Y, Sun X, Humm JL, Ling CC and
O'Donoghue JA: High 18F-FDG uptake in microscopic peritoneal tumors
requires physiologic hypoxia. J Nucl Med. 51:632–638. 2010.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Dence CS, Ponde DE, Welch MJ and Lewis JS:
Autoradiographic and small-animal PET comparisons between
(18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective
(64)Cu-ATSM in a rodent model of cancer. Nucl Med Biol. 35:713–720.
2008. View Article : Google Scholar : PubMed/NCBI
|
12
|
Mudd SR, Holich KD, Voorbach MJ, Cole TB,
Reuter DR, Tapang P, Bukofzer G, Chakravartty A, Donawho CK, Palma
JP, et al: Pharmacodynamic evaluation of irinotecan therapy by FDG
and FLT PET/CT imaging in a colorectal cancer xenograft model. Mol
Imaging Biol. 14:617–624. 2012. View Article : Google Scholar : PubMed/NCBI
|
13
|
Huang T, Civelek AC, Li J, Jiang H, Ng CK,
Postel GC, Shen B and Li XF: Tumor microenvironment-dependent
18F-FDG, 18F-fluorothymidine, and 18F-misonidazole uptake: A pilot
study in mouse models of human non-small cell lung cancer. J Nucl
Med. 53:1262–1268. 2012. View Article : Google Scholar : PubMed/NCBI
|
14
|
Li XF, Huang T, Jiang H, Wang X, Shen B,
Wang X, Ng CK, Postel GC and Civelek AC: Combined injection of
(18)F-fluorodeoxyglucose and 3′-Deoxy-3′-[(18)F]fluorothymidine PET
achieves more complete identification of viable lung cancer cells
in mice and patients than individual radiopharmaceutical: A
proof-of-concept study. Transl Oncol. 6:775–783. 2013. View Article : Google Scholar : PubMed/NCBI
|
15
|
Li XF, Du Y, Ma Y, Postel GC and Civelek
AC: (18)F-fluorodeoxyglucose uptake and tumor hypoxia: Revisit
(18)F-fluorodeoxyglucose in oncology application. Transl Oncol.
7:240–247. 2014. View Article : Google Scholar : PubMed/NCBI
|
16
|
Zhang G, Li J, Wang X, Ma Y, Yin X, Wang
F, Zheng H, Duan X, Postel GC and Li XF: The reverse Warburg effect
and 18F-FDG uptake in non-small cell lung cancer A549 in mice: A
pilot study. J Nucl Med. 56:607–612. 2015. View Article : Google Scholar : PubMed/NCBI
|
17
|
Bunyaviroch T and Coleman RE: PET
evaluation of lung cancer. J Nucl Med. 47:451–469. 2006.PubMed/NCBI
|
18
|
Graves EE, Maity A and Le QT: The tumor
microenvironment in non-small-cell lung cancer. Semin Radiat Oncol.
20:156–163. 2010. View Article : Google Scholar : PubMed/NCBI
|
19
|
Vesselle H, Grierson J, Muzi M, Pugsley
JM, Schmidt RA, Rabinowitz P, Peterson LM, Vallières E and Wood DE:
In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine
([(18)F]FLT) as a proliferation imaging tracer in humans:
Correlation of [(18)F]FLT uptake by positron emission tomography
with Ki-67 immunohistochemistry and flow cytometry in human lung
tumors. Clin Cancer Res. 8:3315–3323. 2002.PubMed/NCBI
|
20
|
Tian J, Yang X, Yu L, Chen P, Xin J, Ma L,
Feng H, Tan Y, Zhao Z and Wu W: A multicenter clinical trial on the
diagnostic value of dual-tracer PET/CT in pulmonary lesions using
3′-deoxy-3′-18F-fluorothymidine and 18F-FDG. J Nucl Med.
49:186–194. 2008. View Article : Google Scholar : PubMed/NCBI
|
21
|
van Waarde A, Cobben DC, Suurmeijer AJ,
Maas B, Vaalburg W, de Vries EF, Jager PL, Hoekstra HJ and Elsinga
PH: Selectivity of 18F-FLT and 18F-FDG for differentiating tumor
from inflammation in a rodent model. J Nucl Med. 45:695–700.
2004.PubMed/NCBI
|
22
|
Grierson JR and Shields AF: Radiosynthesis
of 3′-deoxy-3′-[(18)F]fluorothymidine: [(18)F]FLT for imaging of
cellular proliferation in vivo. Nucl Med Biol. 27:143–156. 2000.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Tarkin JM, Joshi FR and Rudd JH: PET
imaging of inflammation in atherosclerosis. Nat Rev Cardiol.
11:443–457. 2014. View Article : Google Scholar : PubMed/NCBI
|
24
|
Higashi K, Ueda Y, Seki H, Yuasa K, Oguchi
M, Noguchi T, Taniguchi M, Tonami H, Okimura T and Yamamoto I:
Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung
carcinoma. J Nucl Med. 39:1016–1020. 1998.PubMed/NCBI
|
25
|
Kurdziel K, Ravizzini G, Croft B, Tatum J,
Choyke P and Kobayashi H: The evolving role of nuclear molecular
imaging in cancer. Expert Opin Med Diagn. 2:829–842. 2008.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Wang X, Wang X, Zhao Z and Li XF: The
mismatched intratumoral distribution of 18F-FLT and
18F-FDG may be a better indicator of malignancy: A
PET/CT study in patients with solitary pulmonary nodule. J Nucl
Med. 56 Suppl 3:S1242015.
|